Inhibitory effect of soluble EP2 receptor on ovarian tumor growth in nude mice and utility of TMPRSS4 as a combinatorial molecular target

International Journal of Oncology

Volumn 43, Issue 2, 2013, Pages 416-424

  Takahashi, Tetsuyuki ^a   Uehara, Hisanori ^a   Izumi, Keisuke ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Decoy receptor; Ovarian cancer; Soluble EP2 receptor; Transmembrane protease serin 4

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450 1B1; INTERLEUKIN 6; INTERLEUKIN 8; MATRILYSIN; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROTEIN; TRANSMEMBRANE PROTEASE SERIN 4; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CAPILLARY DENSITY; CELL VIABILITY; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GROWTH RATE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; ASCITIC FLUID; CELL PROLIFERATION; CHEMOKINE CXCL1; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; KI-67 ANTIGEN; MATRIX METALLOPROTEINASE 7; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; SIGNAL TRANSDUCTION; SULFONES; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879642097     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1957     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Yokoyama Y, Sakamoto T, Sato S and Saito Y: Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer. Eur J Gynaecol Oncol 20: 361-366, 1999.
3. Wang D and Dubois RN: Prostaglandins and cancer. Gut 55: 115-122, 2006. (Pubitemid 41820645)
4. Freedman RS, Wang E, Voiculescu S, et al: Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. Clin Cancer Res 13: 5736-5744, 2007. (Pubitemid 47583898)
5. Shigemasa K, Tian X, Gu L, Shiroyama Y, Nagai N and Ohama K: Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int J Oncol 22: 99-105, 2003.
6. Daikoku T, Tranguch S, Trofimova IN, et al: Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res 66: 2527-2531, 2006.
7. Coleman RA, Smith WL and Narumiya S: International union pharmacology classification of prostanoid receptors: properties distribution and structure of the receptors and their subtypes. Pharmacol Rev 46: 205-229, 1994. (Pubitemid 24185151)
8. Rask K, Zhu Y, Wang W, Hedin L and Sundfeldt K: Ovarian epithelial cancer: a role to PGE2-synthesis and signaling in malignant transformation and progression. Mol Cancer 5: 62, 2006.
9. Takahashi T, Uehara H, Bando Y and Izumi K: Soluble EP2 neutralizes prostaglandin E2-induced cell signaling and inhibits osteolytic tumor growth. Mol Cancer Ther 7: 2807-2816, 2008.
10. Takahahshi T, Ogawa H, Izumi K and Uehara H: The soluble EP2 receptor FuEP2/Ex2 suppresses endometrial cancer cell growth in an orthotopic xenograft model in nude mice. Cancer Lett 306: 67-75, 2011.
11. Shiirevnyamba A, Takahashi T, Shan H, et al: Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts. Br J Cancer 104: 505-513, 2011.
12. Mori M, Barnard GF, Mimori K, Ueo H, Akiyoshi T and Sugimachi K: Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas. Cancer 75: 1516-1519, 1995.
13. Honda M, Mori M, Ueo H, Sugimachi K and Akiyoshi T: Matrix metalloproteinase-7 expression in gastric carcinoma. Gut 39: 444-448, 1996. (Pubitemid 26338536)
14. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH and McMillan A: ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann Surg 242: 353-361, 2005.
15. Kim S, Kang HY, Nam EH, et al: TMPRSS4 induces invasion and epithelial-mesenchymal transition through upregulation of integrin alpha5 and its signaling pathways. Carcinogenesis 31: 597-606, 2010.
16. McFadyen MC, Cruickshank ME, Miller ID, et al: Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer 85: 242-246, 2001. (Pubitemid 32695746)
17. Heinonen PK and Metsä-Ketelä T: Prostaglandin and thromboxane production in ovarian cancer tissue. Gynecol Obstet Invest 18: 225-229, 1984.
18. Schmidt C, Laporte A and De Baetselier P: Differential responsiveness of murine T lymphomas to local growth and invasion factors may determine metastasis formation in the ovaries. Invasion Metastasis 17: 53-61, 1997.
19. Spinella F, Rosanò L, Di Castro V, Natali PG and Bagnato A: Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 279: 46700-46705, 2004. (Pubitemid 39523128)
20. Li W, Ji ZL, Zhuo GC, Xu RJ, Wang J and Jiang HR: Effects of selective cyclooxygenase-1 inhibitor in SKOV-3 ovarian carcinoma xenograft-bearing mice. Med Oncol 27: 98-104, 2010.
21. Uddin S, Ahmed M, Hussain A, et al: Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer 126: 382-394, 2010.
22. Yang WL, Cai KQ, Smedberg JL, et al: A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice. Am J Pathol 170: 1325-1336, 2007. (Pubitemid 47339339)
23. Orman B, Reina S, Sterin-Borda L and Borda E: Signaling pathways leading to prostaglandin E(2) production by rat cerebral frontal cortex. Prostaglandins Leukot Essent Fatty Acids 74: 255-262, 2006.
24. Sales KJ, Grant V and Jabbour HN: Prostaglandin E2 and F2alpha activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response element. Mol Cell Endocrinol 285: 51-61, 2008.
25. Mesiano S, Ferrara N and Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153: 1249-1256, 1998. (Pubitemid 28465848)
26. Bolitho C, Hahn MA, Baxter RC and Marsh DJ: The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocr Relat Cancer 17: 929-940, 2010.
27. Erroi A, Sironi M, Chiaffarino F, Chen ZG, Mengozzi M and Mantovani A: IL-1 and IL-6 release by tumor-associated macropharges from human ovarian carcinoma. Int J Cancer 44: 795-801, 1989. (Pubitemid 20007974)
28. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD and Fidler IJ: Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90: 447-454, 1998. (Pubitemid 28160636)
29. Wang X and Klein RD: Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP. Mol Carcinog 46: 912-923, 2007. (Pubitemid 350058411)
30. Wang D, Wang H, Brown J, et al: CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 203: 941-951, 2006.
31. Ray A, Sassone-Corsi P and Sehgal PB: A multiple cytokine- and second messenger-responsive element in the enhancer of the human interleukin-6 gene: similarities with c-fos gene regulation. Mol Cell Biol 9: 5537-5547, 1989. (Pubitemid 20004372)
32. Caristi S, Piraino G, Cucinotta M, Valenti A, Loddo S and Teti D: Prostaglandin E2 induces interleukin-8 gene transactivation by activating C/EBP homologous protein in human T lymphocytes. J Biol Chem 280: 14433-14442, 2005. (Pubitemid 40562783)
33. + Th1 cells. J Immunol 187: 1157-1165, 2011.
34. Jung H, Lee KP, Park SJ, et al: TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition. Oncogene 27: 2635-2647, 2008. (Pubitemid 351550879)
35. Sarkar S, Hobson AR, Hughes A, et al: The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology 124: 18-25, 2003. (Pubitemid 36055334)
36. Antonova M, Wienecke T, Maubach K, Thomas E, Olesen J and Ashina M: The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 humanmodel of headache. J Headache Pain 12: 551-559, 2011. Technology Technology